evolutionary genomics inc - FNAM

FNAM

Close Chg Chg %
0.00 0.00 0.00%

Open Market

0.00

0.00 (0.00%)

Volume: 1.00K

Last Updated:

Oct 31, 2025, 10:21 AM EDT

Company Overview: evolutionary genomics inc - FNAM

FNAM Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.00

Market Cap

$0.00

Shares Outstanding

6.66M

Public Float

4.48M

Beta

-0.21

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.35

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

FNAM Performance

No Data Available

FNAM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About evolutionary genomics inc - FNAM

Evolutionary Genomics, Inc. is a genomics research and development company, which engages in the identification and validation of genes. It performs research on crops including rice, corn, soybeans, wheat, cotton, cowpeas, beans, tomatoes, and cassava. The company was founded by Walter Messier and Virginia Orndorff in November 1990 and is headquartered in Castle Rock, CO.

FNAM At a Glance

Evolutionary Genomics, Inc.
4220 Morning Star Drive
Castle Rock, Colorado 80108
Phone 1-303-862-3222 Revenue 0.00
Industry Miscellaneous Net Income -1,934,967.00
Sector Miscellaneous Employees 4
Fiscal Year-end 12 / 2023
View SEC Filings

FNAM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -13.58
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.278

FNAM Efficiency

Revenue/Employee N/A
Income Per Employee -483,741.75
Receivables Turnover N/A
Total Asset Turnover N/A

FNAM Liquidity

Current Ratio 3.921
Quick Ratio 3.921
Cash Ratio 3.238

FNAM Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -73.214
Return on Equity N/A
Return on Total Capital -88.945
Return on Invested Capital -76.05

FNAM Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 172.089
Total Debt to Total Assets 159.057
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 172.089
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Evolutionary Genomics Inc - FNAM

Collapse All in section
All values USD millions. 2019 2020 2021 2022 5-year trend
Sales/Revenue
- - 122.69K 12.50K
-
Sales Growth
- +6.86% -89.81% -100.00%
Cost of Goods Sold (COGS) incl D&A
- - 1.04M 1.02M
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
40.72K 409.37K 1.04M 1.02M
Depreciation
38.12K 38.12K 32.07K 14.74K
Amortization of Intangibles
2.60K 371.25K 1.01M 1.01M
COGS Growth
- - - -1.67%
-
Gross Income
- - (1.04M) (1.02M)
-
Gross Income Growth
- - - +1.67%
-
Gross Profit Margin
- - - -
-
2019 2020 2021 2022 5-year trend
SG&A Expense
856.79K 2.48M 1.84M 992.81K
Research & Development
472.61K 1.79M 1.23M 417.45K
Other SG&A
384.18K 689.78K 604.91K 575.36K
SGA Growth
-5.90% +189.79% -25.93% -46.02%
Other Operating Expense
- - - -
-
Unusual Expense
(13.49K) (74.27K) (83.39K) (78.00K)
EBIT after Unusual Expense
(761.33K) (2.81M) (2.79M) (1.94M)
Non Operating Income/Expense
98 106.29K 604 1.33K
Non-Operating Interest Income
98 372 604 1.33K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(761.23K) (2.70M) (2.79M) (1.93M)
Pretax Income Growth
+30.71% -254.59% -3.51% +30.74%
Pretax Margin
- - -620.47% -21,593.89%
-
Income Tax
- - 31.91K (987.35K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - 31.91K (987.35K)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(793.14K) (1.71M) (2.79M) (1.93M)
Minority Interest Expense
- - - -
-
Net Income
(793.14K) (1.71M) (2.79M) (1.93M)
Net Income Growth
+27.81% -115.84% -63.21% +30.74%
Net Margin Growth
- - -646.48% -13,695.06%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(793.14K) (1.71M) (2.79M) (1.93M)
Preferred Dividends
269.38K 285.57K 285.57K 313.29K
Net Income Available to Common
(1.06M) (2.00M) (3.08M) (2.25M)
EPS (Basic)
-0.1806 -0.3396 -0.5236 -0.3481
EPS (Basic) Growth
+20.79% -88.04% -54.18% +33.52%
Basic Shares Outstanding
5.88M 5.88M 5.88M 6.46M
EPS (Diluted)
-0.1806 -0.3396 -0.5236 -0.3481
EPS (Diluted) Growth
+20.79% -88.04% -54.18% +33.52%
Diluted Shares Outstanding
5.88M 5.88M 5.88M 6.46M
EBITDA
(734.10K) (2.47M) (1.84M) (992.81K)
EBITDA Growth
+7.74% -236.52% +25.55% +46.02%
EBITDA Margin
- - -598.36% -19,763.44%
-

Evolutionary Genomics Inc in the News